Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies
Stacey E.
Rudd
a,
Peter
Roselt
b,
Carleen
Cullinane
bc,
Rodney J.
Hicks
*cd and
Paul S.
Donnelly
*a
aSchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria 3010, Australia. E-mail: pauld@unimelb.edu.au
bResearch Division, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne 3000, Victoria, Australia
cThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia. E-mail: Rod.Hicks@petermac.org
dCentre for Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne 3000, Victoria, Australia
First published on 9th September 2016
Abstract
Correction for ‘A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies’ by Stacey E. Rudd et al., Chem. Commun., 2016, DOI: 10.1039/c6cc05961a.
The authors regret that a significant reference was omitted from the original article. A citation to work by Gasser, Mindt and co-workers should have been included in the first page.
“The addition of an extra hydroxamic acid functional group to give an octadentate variant called DFO* resulted in improved stability of 89ZrIV complexes but the ligand suffers from limited solubility in aqueous environments.1”
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
References
- M. Patra, A. Baumann, C. Mari, C. A. Fischer, O. Blacque, D. Häussinger, G. Gasser and T. L. Mindt, Chem. Commun., 2014, 50, 11523–11525 RSC.
| This journal is © The Royal Society of Chemistry 2016 |